Rodriguez-Garcia Alba, Watanabe Keisuke, Guedan Sonia
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Methods Mol Biol. 2020;2086:251-271. doi: 10.1007/978-1-0716-0146-4_19.
Animal models provide an essential tool to study the efficacy of CAR-T cell treatments. Most of the current works test human CAR-T cells in immunodeficient animals, typically NOD Scid Gamma (NSG) mice transplanted with human tumors. Despite the limitations of this model, including the difficulty to study the interaction between CAR-T cells and the human innate system and to assess the toxicity of this therapy, NSG are extensively used for adoptive T cell transfer studies. In this chapter, we will describe the protocols to test CAR-T cells in NSG animals with solid tumors. We first describe the implantation of human xenograft tumors in NSG animals, followed by CAR-T cell administration and assessment of antitumor responses. We will also review the protocols to analyze T cell persistence in the blood of treated animals. Finally, we will focus on the analysis of the tumors at the end point of the experiment, including the percentage, phenotype, and function of tumor infiltrating T cells, and loss of antigen expression.
动物模型为研究嵌合抗原受体T细胞(CAR-T)治疗的疗效提供了重要工具。目前大多数研究在免疫缺陷动物中测试人CAR-T细胞,通常是移植了人肿瘤的非肥胖糖尿病/重症联合免疫缺陷(NOD)小鼠(NOD Scid Gamma,NSG)。尽管该模型存在局限性,包括难以研究CAR-T细胞与人类先天免疫系统之间的相互作用以及评估该疗法的毒性,但NSG小鼠仍被广泛用于过继性T细胞转移研究。在本章中,我们将描述在患有实体瘤的NSG动物中测试CAR-T细胞的方案。我们首先描述在NSG动物中植入人异种移植肿瘤,随后进行CAR-T细胞给药并评估抗肿瘤反应。我们还将回顾分析经治疗动物血液中T细胞持久性的方案。最后,我们将重点关注实验终点时肿瘤的分析,包括肿瘤浸润T细胞的百分比、表型和功能,以及抗原表达的丧失。